-
公开(公告)号：US11352438B2
公开(公告)日：2022-06-07
申请号：US16330269
申请日：2017-09-05
摘要： An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and/or treated more effectively.
-
公开(公告)号：US20190194352A1
公开(公告)日：2019-06-27
申请号：US16330269
申请日：2017-09-05
CPC分类号： C07K16/36 , A61K2039/505 , A61K2039/54 , A61K2039/545 , A61P7/04 , C07K2317/24 , C07K2317/31 , C07K2317/94
摘要： An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and/or treated more effectively.
-
公开(公告)号：US20220315667A1
公开(公告)日：2022-10-06
申请号：US17828752
申请日：2022-05-31
摘要： An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and/or treated more effectively.
-
公开(公告)号：US20230159658A1
公开(公告)日：2023-05-25
申请号：US18156559
申请日：2023-01-19
CPC分类号： C07K16/36 , A61P7/04 , C07K2317/24 , C07K2317/31 , C07K2317/94 , A61K2039/545
摘要： An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and/or treated more effectively.
-
公开(公告)号：US20240052058A1
公开(公告)日：2024-02-15
申请号：US18466900
申请日：2023-09-14
CPC分类号： C07K16/36 , A61P7/04 , C07K2317/24 , C07K2317/31 , C07K2317/94 , A61K2039/545
摘要： An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and/or treated more effectively.
-
公开(公告)号：US20240317891A1
公开(公告)日：2024-09-26
申请号：US18734434
申请日：2024-06-05
发明人： Koichiro Yoneyama
IPC分类号： C07K16/36 , A61K39/00 , A61K39/395 , C07K16/46
CPC分类号： C07K16/36 , A61K39/395 , C07K16/46 , A61K2039/505 , C07K2317/31 , C07K2317/51 , C07K2317/515
摘要： The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor IX and/or activated blood coagulation factor IX and blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, diseases that develop and/or progress due to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII can be prevented and/or treated more effectively.
-
公开(公告)号：US20190309090A1
公开(公告)日：2019-10-10
申请号：US16432790
申请日：2019-06-05
发明人： Koichiro Yoneyama
IPC分类号： C07K16/36 , C07K16/46 , A61K39/395
摘要： The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor IX and/or activated blood coagulation factor IX and blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, diseases that develop and/or progress due to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII can be prevented and/or treated more effectively.
-
公开(公告)号：US20170253663A1
公开(公告)日：2017-09-07
申请号：US15319016
申请日：2015-03-31
发明人： Koichiro Yoneyama
IPC分类号： C07K16/36
CPC分类号： C07K16/36 , A61K39/395 , A61K2039/505 , C07K16/46 , C07K2317/31 , C07K2317/51 , C07K2317/515
摘要： The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor IX and/or activated blood coagulation factor IX and blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, diseases that develop and/or progress due to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII can be prevented and/or treated more effectively.
-
公开(公告)号：US20220324999A1
公开(公告)日：2022-10-13
申请号：US17849879
申请日：2022-06-27
发明人： Koichiro Yoneyama
IPC分类号： C07K16/36 , A61K39/395 , C07K16/46
摘要： The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor IX and/or activated blood coagulation factor IX and blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, diseases that develop and/or progress due to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII can be prevented and/or treated more effectively.
-
公开(公告)号：US20210238307A1
公开(公告)日：2021-08-05
申请号：US17235445
申请日：2021-04-20
发明人： Koichiro Yoneyama
IPC分类号： C07K16/36 , A61K39/395 , C07K16/46
摘要： The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor IX and/or activated blood coagulation factor IX and blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, diseases that develop and/or progress due to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII can be prevented and/or treated more effectively.
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.021 秒)
